ERBB2 and breast cancer: Consistent with primary tumors, metastatic BC from the K-MASTER cohort exhibited a higher proportion of HER2 + and TNBC-type tumors, while MSK-IMPACT was predominantly composed of HR + patients (Fig. 2A).